公开(公告)号：US20130005771A1

公开(公告)日：2013-01-03

申请号：US13580928

申请日：2011-02-24

申请人： Meenakshi Sivakumar ,  Kalpana Sanjay Joshi ,  Valmik Sopan Aware ,  Ankush Gangaram Sarde ,  Sandeep Maruti Bagul ,  Sonal Mohan Manohar

发明人： Meenakshi Sivakumar ,  Kalpana Sanjay Joshi ,  Valmik Sopan Aware ,  Ankush Gangaram Sarde ,  Sandeep Maruti Bagul ,  Sonal Mohan Manohar

IPC分类号： A61K31/4245 ,  C07D413/06 ,  A61P35/02 ,  C07D413/04 ,  A61K31/4439 ,  A61P35/00 ,  C07D271/06 ,  A61K31/454

CPC分类号： C07D271/06 ,  C07D413/06

摘要： The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

摘要翻译： 本发明涉及所有其立体异构互变异构形式的恶二唑化合物及其混合物; 及其药学上可接受的盐，药学上可接受的溶剂化物，药学上可接受的前药和药学上可接受的多晶型物。 本发明还涉及制备恶二唑化合物的方法和含有它们的药物组合物。 所述化合物及其药物组合物可用于治疗癌症，特别是慢性骨髓性白血病（CML）。 本发明还提供了一种通过向有需要的哺乳动物施用治疗有效量的所述化合物或其药物组合物来治疗癌症的方法。

公开(公告)号：US08629277B2

公开(公告)日：2014-01-14

申请号：US13580928

申请日：2011-02-24

申请人： Meenakshi Sivakumar ,  Kalpana Sanjay Joshi ,  Valmik Sopan Aware ,  Ankush Gangaram Sarde ,  Sandeep Maruti Bagul ,  Sonal Mohan Manohar

发明人： Meenakshi Sivakumar ,  Kalpana Sanjay Joshi ,  Valmik Sopan Aware ,  Ankush Gangaram Sarde ,  Sandeep Maruti Bagul ,  Sonal Mohan Manohar

IPC分类号： C07D413/06 ,  C07D271/06

CPC分类号： C07D271/06 ,  C07D413/06

摘要： The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

摘要翻译： 本发明涉及所有其立体异构互变异构形式的恶二唑化合物及其混合物; 及其药学上可接受的盐，药学上可接受的溶剂化物，药学上可接受的前药和药学上可接受的多晶型物。 本发明还涉及制备恶二唑化合物的方法和含有它们的药物组合物。 所述化合物及其药物组合物可用于治疗癌症，特别是慢性骨髓性白血病（CML）。 本发明还提供了一种通过向有需要的哺乳动物施用治疗有效量的所述化合物或其药物组合物来治疗癌症的方法。